Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
RAMSAY HEALTH CARE LIMITED (RHC)ASX AI Signals has generated 2 signal(s) for RHC during the last 90 days, indicating Moderate trading activity
Latest RHC Signals | |
| 03/06/2026 | SELL |
| 17/04/2026 | BUY |
| 17/03/2026 | BUY |
RHC Share Price | |
| Current Price | $44.160 |
| 52 Week High | $44.160 |
| 52 Week Low: | $30.308 |
| Trading at (% of 52 Week High) | 100.00% |
Ramsay Health Care Limited (ASX: RHC) is a global healthcare provider operating a network of hospitals and clinics. The company offers a range of medical and surgical services, including elective and emergency care, across Australia, Europe, and Asia. Ramsay focuses on delivering quality patient care through its private hospital facilities.
The Health Care Equipment & Services sector on the ASX includes companies that produce medical devices, equipment, and supplies, as well as those providing healthcare-related services. This sector covers a wide range of products such as surgical instruments, diagnostic machines, and health monitoring devices. It also includes businesses involved in healthcare management, medical laboratories, and support services. These companies play a key role in supporting hospitals, clinics, and other healthcare providers to improve patient care. The sector is influenced by factors like technological advances, regulatory changes, and demand for healthcare services.
The SELL recommendation for RAMSAY HEALTH CARE LIMITED (RHC) is supported by moderate bearish signals, but the overall market conditions and company fundamentals suggest caution. The confidence level is medium due to mixed indicators and sector stability.
RAMSAY SANTE
PRESS RELEASE
Paris, 24th June 2026
Ramsay Santé launches senior debt refinancing
Ramsay Santé today announces the launch of a €1.75 billion refinancing of its senior debt, comprising a €200 million revolving credit facility and a €1.55 billion Term Loan B (the "Transaction").
The Psyence Biomedical Ltd.
Expansion supports accelerated enrollment and advancement of the Company’s lead clinical asset
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psiloc Investors who take an interest in Ramsay Health Care Limited (ASX:RHC) should definitely note that the Independent Non-Executive Director, Craig Drummond, recently paid AU$40.19 per share to buy AU$603k worth of the stock. However, it only increased shareholding by a small percentage, and it wasn't Find insight on Merck, Sonic Healthcare and more in the latest Market Talks covering the health care sector.
Continue Reading This article first appeared on GuruFocus.
Underlying EBIT Growth: 7.3% increase, driven by Australia. Underlying NPAT Growth: 8.1% increase. Dividend: Fully franked dividend of $0.42 per share, up 6.3%, with a 60% payout ratio. Revenue from Customers: Increased by 8.2%, driven by a 3.1% increase inLatest RAMSAY HEALTH CARE LIMITED(RHC) News
RAMSAY SANTE launches senior debt refinancing
Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
Craig Drummond Buys Handful Of Shares In Ramsay Health Care
Health Care Roundup: Market Talk
Ramsay Health Care Ltd (RMYHY) (Half Year 2026) Earnings Call Highlights: Strong Australian ...
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial